Gilead Sciences v. Meritain Health — Foreign-Market Drugs Can Infringe Despite Chemical Identity

Background

Gilead manufactures Biktarvy and other prescription drugs for different national markets. Although the pills sold abroad may have the same chemical formulation as their U.S. counterparts, the packaging, warnings, regulatory information, distribution chain, and recall procedures differ by country.

The dispute began after a Maryland patient expected to receive U.S. Biktarvy but instead received a bottle packaged for Turkey. His employer used a self-funded health plan administered by Meritain Health, with ProAct serving as the pharmacy benefit manager. The system directed the patient away from the ordinary domestic pharmacy network to Rx Valet, which arranged international sourcing through affiliated and foreign entities. Gilead’s investigation found that the same arrangement had supplied hundreds of bottles of foreign-market Gilead medicines to U.S. patients.

Gilead sued for trademark infringement and unfair competition under the Lanham Act. The district court entered a preliminary injunction barring Meritain, ProAct, Rx Valet, and related participants from importing, advertising, selling, or facilitating foreign-market Gilead products in the United States. The defendants appealed.

The Court’s Holding

The Fourth Circuit affirmed. It held that Gilead was likely to succeed in showing that the imported medicines were not “genuine” goods for Lanham Act purposes, even though Gilead manufactured them and their active formulation was chemically identical to the U.S. version. The court adopted the widely used material-differences doctrine for gray-market goods: an unauthorized foreign product is not genuine when even a slight difference would likely matter to consumers.

The Turkish Biktarvy had Turkish-language packaging and omitted information found on the U.S. product, including an FDA-required boxed warning, the National Drug Code, storage instructions, and U.S. adverse-event contacts. Those differences were especially important for prescription medicines. The court rejected the argument that patients could simply search online for missing information; consumers seeing Gilead’s marks reasonably expect the product they receive to include the characteristics and safeguards of the authorized U.S. version.

The imported medicines also bypassed Gilead’s U.S. quality-control system. Domestic shipments use temperature monitoring, traceable pedigrees, a closed network of authorized distributors, and U.S. recall procedures. The international-sourcing chain did not give Gilead the same ability to investigate temperature excursions, trace custody, or notify affected U.S. patients of a foreign recall. Trademark law protects the owner’s right to control quality associated with its marks, not merely the physical quality of the product. Because the medicines were materially different and outside Gilead’s legitimate quality controls, the first-sale doctrine did not defeat the infringement claims.

The court also agreed that Gilead was likely to establish contributory liability against service providers that continued supplying data, referrals, payment processing, and other essential assistance with knowledge of the infringement. Gilead received the statutory presumption of irreparable harm, and its investigation before filing suit did not negate urgency. The balance of equities and public interest supported stopping distribution of non-genuine prescription drugs.

Key Takeaways

• A branded product can be authentic in the everyday sense yet non-genuine under trademark law when a foreign-market version materially differs from the authorized U.S. product.
• Packaging, safety warnings, traceability, temperature controls, and recall coverage can be material even when two medicines have the same chemical formulation.
• The first-sale doctrine does not protect resale of goods that bypass the trademark owner’s legitimate, substantial, and nonpretextual quality-control system.
• Administrators and intermediaries can face contributory trademark liability when their services are essential to a known infringement chain.

Why It Matters

The ruling gives brand owners in the Fourth Circuit a strong tool against gray-market imports, particularly for regulated products where labeling and distribution safeguards matter. Importers and benefit-plan vendors cannot rely only on chemical identity or foreign authenticity; they must evaluate whether the product differs from the U.S. version and whether it remains inside the brand owner’s quality-control system.

The opinion’s cover page lists “August 13, 2025,” but the case was argued in May 2026 and the Fourth Circuit released it on August 13, 2026. LexSummary therefore uses August 13, 2026 as the decision date.

Surfaced via Law360 IP.